Quarterly report · Q1
2503.TEDINET S100TE18
Period2024-01-01 → 2024-03-31
Filed2024-05-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥501.8bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥450.3bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥30.8bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥11.0bn | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥44.2bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥25.9bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.6bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥32.6bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥11.3bn | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.00T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.47T | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.55T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.44T | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.46T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.23T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.25T | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.16T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥971.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥151.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥116.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥39.9bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥41.9bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥65.3bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥31.4bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥34.7bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥8.6bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.98 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥6.9 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 38.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-03-31 | ¥20.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥15.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-03-31 | −¥158m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-03-31 | −¥17.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥12.3bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥238.6bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥238.2bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥379m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥32.7bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥31.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥726m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥1.7bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥122.2bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥121.5bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥645m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥12.2bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥105.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥105.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-03-31 | ¥67m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥16.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-03-31 | ¥22.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-03-31 | ¥6.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥16.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-03-31 | −¥265m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥11.5bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥225.4bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥225.1bn |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥300m |
| jpcrp040300-q1r_E00395-000Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥20.9bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥18.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥17.4bn |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥991m |
| jpcrp040300-q1r_E00395-000Health Sciencereportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥1.4bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥108.6bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥108.0bn |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥609m |
| jpcrp040300-q1r_E00395-000Non Alcoholic Beveragesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥9.6bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥93.5bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥93.4bn |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥107m |
| jpcrp040300-q1r_E00395-000Pharmaceuticalsreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥16.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 779
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in deposits received ope cf IFRS | CurrentYTDDuration | -5229000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -16789000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -21015000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 45838000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 44574000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 6310000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 9533000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -491000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -1293000000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YTDDuration | -9801000000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYTDDuration | -12931000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 41857000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 39883000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | -28933000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | -21999000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | Prior1YTDDuration | 1390000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | CurrentYTDDuration | 3330000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YTDDuration | -226000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYTDDuration | -509000000 | JPY |
| Proceeds from sales of investments inv cf IFRS | Prior1YTDDuration | 155000000 | JPY |
| Proceeds from sales of investments inv cf IFRS | CurrentYTDDuration | 679000000 | JPY |
| Purchase of shares of subsidiaries inv cf IFRS | Prior1YTDDuration | － | JPY |
| Purchase of shares of subsidiaries inv cf IFRS | CurrentYTDDuration | -45062000000 | JPY |
| Payment for sale of shares of subsidiary due to change in scope of consolidation inv cf IFRS | Prior1YTDDuration | -5006000000 | JPY |
| Payment for sale of shares of subsidiary due to change in scope of consolidation inv cf IFRS | CurrentYTDDuration | － | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | Prior1YTDDuration | -18000000 | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | CurrentYTDDuration | -5000000 | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | Prior1YTDDuration | 12000000 | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | CurrentYTDDuration | － | JPY |
| Other inv cf IFRS | Prior1YTDDuration | 1217000000 | JPY |
| Other inv cf IFRS | CurrentYTDDuration | -1779000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -31409000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -65345000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YTDDuration | -30000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYTDDuration | 1752000000 | JPY |
| Increase decrease in commercial paper fin cf IFRS | Prior1YTDDuration | -8000000000 | JPY |
| Increase decrease in commercial paper fin cf IFRS | CurrentYTDDuration | 19000000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YTDDuration | 50000000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYTDDuration | 101977000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -10000000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -21664000000 | JPY |
| Payment for redemption of bonds with subscription rights to shares fin cf IFRS | Prior1YTDDuration | － | JPY |
| Payment for redemption of bonds with subscription rights to shares fin cf IFRS | CurrentYTDDuration | -9621000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -4307000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -4831000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -6000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -14000000 | JPY |
| Purchase of treasury stock of subsidiaries in consolidation fin cf IFRS | Prior1YTDDuration | -2000000 | JPY |
| Purchase of treasury stock of subsidiaries in consolidation fin cf IFRS | CurrentYTDDuration | -7404000000 | JPY |
| Decrease increase in deposits for purchase of treausury shares of subsidiaries fin cf IFRS | Prior1YTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |